MedTrace Logo

Suvorexant in Insomnia Co-morbid With Fibromyalgia

NCT02684136 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-06-16

Study results available
· View outcomes & findings →

Summary

This study will compare sleep, pain and daytime sleepiness/fatigue in people with insomnia co-morbid with fibromyalgia while treated short-term with suvorexant 20 mg versus placebo.

Conditions

Interventions

DRUG

suvorexant

suvorexant 20 mg taken before sleep

DRUG

placebo

placebo taken before sleep

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Principal Investigators

  • Timothy Roehrs, PhD · Henry Ford Health System

  • Thomas Roth, PhD · Henry Ford Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2018-07-01
Completion
2018-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02684136 on ClinicalTrials.gov